[SCHEDULE 13G] Amylyx Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Amylyx Pharmaceuticals has a passive ownership filing showing that FMR LLC and Abigail P. Johnson together report beneficial ownership of 11,379,207 shares of common stock, representing 10.7% of the outstanding class. The filing shows FMR LLC holds 11,361,910 shares with sole voting power for that portion and sole dispositive power over 11,379,207 shares, while Abigail P. Johnson is reported with sole dispositive power over the full 11,379,207 shares and no voting power. The statement clarifies the stake is held in the ordinary course of business and not to change control.

Positive

• Material stake disclosed: 11,379,207 shares equals 10.7% of the class, providing clear transparency
• Held in ordinary course: Certification states the position was not acquired to change control

Negative

• Voting power limited: Report shows 0 shared voting power and limited sole voting power relative to dispositive power
• Potential market impact: A 10.7% block could affect float and liquidity if disposition occurs

Insights

Institutional Ownership Analyst

Fidelity-affiliated entities report a material passive stake of 10.7%.

The combined 11.38M share position represents a substantial minority ownership that can affect float and trading liquidity. The split between voting and dispositive powers shows FMR LLC holds near-total dispositive control while reported voting power for that entity is slightly lower.

Risks and dependencies include any future schedule amendments if voting arrangements change; monitor subsequent filings for voting power shifts or sales activity within the next quarters.

Corporate Governance Analyst

Ownership is reported as held in the ordinary course and not for control.

The filing explicitly certifies the securities were not acquired to influence control, which limits immediate governance implications. However, owning 10.7% can still create informal influence through engagement or voting if the holder chooses to act.

Watch for any proxy disclosures, Schedule 13D filings, or changes in voting power that would signal a shift from passive to active ownership.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

AMYLYX PHARMACEUTICALS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

03237H101

(CUSIP Number)

09/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 03237H101

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 11,361,910.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 11,379,207.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,379,207.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.7 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 03237H101

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 11,379,207.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,379,207.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.7 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: AMYLYX PHARMACEUTICALS INC
(b)	Address of issuer's principal executive offices: 43 THORNDIKE STREET,CAMBRIDGE,MA,USA,02141
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 03237H101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 11379207.00
(b)	Percent of class: 10.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 11379207.00
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of AMYLYX PHARMACEUTICALS INC. No one other person's interest in the COMMON STOCK of AMYLYX PHARMACEUTICALS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	10/06/2025

Abigail P. Johnson

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:	10/06/2025

Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.

FAQ

What stake did FMR LLC and Abigail P. Johnson report in Amylyx (AMLX)?

They reported beneficial ownership of 11,379,207 shares, representing 10.7% of the common stock.

Does FMR LLC have voting control over the reported Amylyx shares?

The filing shows FMR LLC has 11,361,910 shares of sole voting power for part of the position and 0 shared voting power; dispositive power is reported for 11,379,207 shares.

Is the Amylyx stake intended to change company control?

The certification states the securities were acquired and are held in the ordinary course of business and not to change or influence control.

Will this Schedule 13G trigger governance actions at Amylyx?

The filing is a passive 13G disclosure; it does not by itself trigger governance changes, though a shift to active intent would require different filings.

How material is a 10.7% holding for AMLX investors?

A 10.7% position is material because it represents a large minority stake that could affect trading liquidity or become influential if voting intentions change.